Castle Biosciences Inc (CSTL) - Total Assets
Based on the latest financial reports, Castle Biosciences Inc (CSTL) holds total assets worth $547.80 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Castle Biosciences Inc (CSTL) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Castle Biosciences Inc - Total Assets Trend (2017–2025)
This chart illustrates how Castle Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See what is Castle Biosciences Inc's book value for net asset value and shareholders' equity analysis.
Castle Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Castle Biosciences Inc's total assets of $547.80 Million consist of 62.4% current assets and 37.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.2% |
| Accounts Receivable | $43.38 Million | 7.5% |
| Inventory | $10.25 Million | 1.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $88.88 Million | 15.4% |
| Goodwill | $10.69 Million | 1.9% |
Asset Composition Trend (2017–2025)
This chart illustrates how Castle Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CSTL stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Castle Biosciences Inc's current assets represent 62.4% of total assets in 2025, a decrease from 68.1% in 2017.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2025, up from 12.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 15.4% of total assets.
Castle Biosciences Inc Competitors by Total Assets
Key competitors of Castle Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
SCOPE FLUIDICS SA ZY-10
F:S84
|
Germany | €195.94 Million |
|
Cytogen Inc
KQ:217330
|
Korea | ₩62.24 Billion |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
Castle Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.75 | 9.37 | 21.00 |
| Quick Ratio | 6.53 | 9.19 | 20.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $280.14 Million | $312.11 Million | $373.05 Million |
Castle Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Castle Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.58 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | 8.9% |
| Total Assets | $578.56 Million |
| Market Capitalization | $722.76 Million USD |
Valuation Analysis
Above Book Valuation: The market values Castle Biosciences Inc's assets above their book value (1.25x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Castle Biosciences Inc's assets grew by 8.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Castle Biosciences Inc (2017–2025)
The table below shows the annual total assets of Castle Biosciences Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $578.56 Million | +8.91% |
| 2024-12-31 | $531.24 Million | +17.18% |
| 2023-12-31 | $453.34 Million | +1.34% |
| 2022-12-31 | $447.33 Million | -3.30% |
| 2021-12-31 | $462.57 Million | +5.29% |
| 2020-12-31 | $439.33 Million | +266.88% |
| 2019-12-31 | $119.75 Million | +434.46% |
| 2018-12-31 | $22.40 Million | +128.15% |
| 2017-12-31 | $9.82 Million | -- |
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis fo… Read more